Company Filing History:
Years Active: 2023
Title: Wendy Benjamin: Innovator in Cancer Treatment Formulations
Introduction
Wendy Benjamin is a notable inventor based in North Brunswick, NJ (US). She has made significant contributions to the field of cancer treatment through her innovative work on antibody formulations. Her research focuses on developing stable formulations of programmed death receptor 1 (PD-1) antibodies, which play a crucial role in cancer therapy.
Latest Patents
Wendy Benjamin holds 1 patent for her invention titled "Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof." This invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The formulations comprise between 5-200 mg/mL of anti-PD-1 antibody, or its antigen binding fragment. Additionally, the invention provides methods for treating various cancers using these stable formulations, which can be administered to a subject either intravenously or subcutaneously.
Career Highlights
Wendy is currently associated with Merck Sharp & Dohme Corp., where she continues to advance her research in the pharmaceutical field. Her work has the potential to significantly impact cancer treatment protocols and improve patient outcomes.
Collaborations
Wendy collaborates with esteemed colleagues such as Manoj K Sharma and Sarita Mittal, contributing to a dynamic research environment focused on innovative cancer therapies.
Conclusion
Wendy Benjamin's contributions to the field of cancer treatment through her patented formulations of PD-1 antibodies highlight her role as a leading inventor in the pharmaceutical industry. Her work exemplifies the importance of innovation in developing effective therapies for cancer patients.